郭桂芳

职务：综合科副主任
职称：主任医师、博士生导师、肿瘤内科学博士、美国佛罗里达大学高级访问学者
专业特长：肿瘤内科治疗（擅长胆胰、肠等消化道肿瘤，肺癌及头颈肿瘤等）； VIP肿瘤患者的治疗管理及保健。
临床试验：主持一项胰腺癌的临床试验，已顺利完成；
专业论文：第一作者/通讯作者SCI论文30余篇；
课题：主持8项科研基金，包括1项国家自然科学基金，6项省级课题，1项中山大学优秀青年校级课题；

学习工作经历：
2020.01—至今： 中山大学附属肿瘤医院综合科 主任医师　　                       
2012.01—2019.12： 中山大学附属肿瘤医院综合科 副主任医师　　　　
2013.08—2014.07：美国佛罗里达大学高级访问学者（博士后工作）
2007.09—2010.06：中山大学附属肿瘤医院（博士生）                                  
2004.08—2011.12：中山大学附属肿瘤医院综合科 主治医师                           
2001.09—2004.06：中山大学附属肿瘤医院（硕士生）
1998.07—2001.08：山西省焦煤集团职工总院 住院医师
1993.09—1998.06：安徽皖南医学院临床医疗系 本科生

学术兼职：
广东省精准医学应用学会肿瘤综合治疗分会副主委
广东省精准医学应用学会头颈肿瘤分会 副主委
广东省保健协会免疫细胞与干细胞治疗分会 副主委
广东省健康科普促进会肿瘤免疫治疗分会 副主委
中国抗癌协会肿瘤靶向治疗专业委员会委员
中国抗癌协会肿瘤临床化疗专业委员会委员
中国抗癌协会肿瘤胰腺病学专业委员会委员
广东省健康管理学会胰腺疾病专业委员会常委
广东省健康管理协会肿瘤防治专业委员会常委
广东省女医师协会老年病防治专业委员会常委
广东抗癌协会肿瘤支持与康复治疗专业委员会常委

科研经历：
一．基金
（一）第一负责人基金
1. 广东省自然科学基，面上项目，2023A1515010783，代谢酶HK2在Cetuximab治疗RAS野生型肠癌疗效预测中的作用及表观调控机制， 2023-01至2025-12, 10万元，在研，主持
2. 广东省自然科学基金，面上项目，2021A030313485，YTHDF3/m6A调控HK2是增敏及预测Cetuximab对肠癌疗效的潜在分子机制，2021-01至2023-12, 10万元，在研，主持
3. 广东省自然科学基金，2017A030313685，干预mTOR/HK2通路抑制糖酵解增敏Cetuximab抗结肠癌疗效的探索，2017.5-2020.5, 10万元，结题，主持;
4. 广东省中医药局科研课题，20171069，鸦胆子油乳通过调控 Beclin1 抑制自噬是其抗肿瘤新机制的研究，2017/01-2019/01，5000元，结题，主持；
5. 国家自然科学基金，81302141，干预SGLT1/AMPK通路诱导自噬增强Cetuximab抗结肠癌疗效的研究，2014/01-2017/12,27万元，结题，主持；
6. 高校基本科研业务费中山大学青年教师培育项目，12ykpy56，SGLT1/AMPK介导Cetuximab诱发结肠癌自噬依赖于mTOR通路的研究，2012/10-2016/09, 15万元，结题，主持；
7. 广东省科技计划项目， 2010B031600317， Cetuximab 下调SGLT1 诱导肠癌细胞自噬为增敏Irinotecan 的新机制。2011/01-2014/12, 10万元，结题，主持;
8. 广东省中医药局科研课题, 20111169，自噬为鸦胆子油乳抗大肠癌的新机制，2011/09-2013/08, 2万元，结题，主持;

二．代表性SCI论文
1.Guifang Guo*# (第一及通讯作者), Yixing Wang#, Yixin Zhou, Qi Quan, Yijun Zhang, Haohua Wang, Bei Zhang and Liangping Xia. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother cancer. 2019 Jul 12;7(1):179-191. (IF=13.7).
2.Jiang Q#, Huang J#, Zhang B, Li X,Chen X, Cui B, Li S* and Guo G* (通讯作者) ，
Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A
Systematic Review and Meta-Analysis. Front. Immunol. 13:801909. March 2022 |，Volume 13 (IF=8.9)
3.Yixing Wang#, Jun Dong#, Qi Quan#, Shousheng Liu, Xiuxing Chen, Xiuyu Cai, Huijuan Qiu, Bei Zhang* and Guifang Guo *(通讯作者). Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy with or without Bevacizumab in Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2021, 10:1-12. (IF=4.8).
4.Qi Quan#, Yixing Wang#, Fenghua Wang, Dongsheng Zhang, Xiuxing Chen, Wenzhuo He , Bei Zhang * and Guifang Guo*(通讯作者). Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Curr. Oncol. 2021, 28: 209–219. (IF=3.7)
5.Gui-Fang Guo*# (第一及通讯作者), Yi-Xing Wang#, Yi-Jun Zhang, Xiu-Xing Chen, Jia-Bin Lu, Hao-Hua Wang, Chang Jiang, Hui-Quan Qiu, Liang-Ping Xia. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world
data. World J Gastroenterol. 2019 Apr 21;25(15):1840-1853. (IF=3.4)
6.Guo G*# (第一及通讯作者), Chen X#, He W, Wang H, Wang Y, Hu P, Rong Y, Fan L, Xia L. Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. PLoS One. 2018 Dec 4;13(12):e0208547. (IF=2.8). 
7.Jinsheng Huang#, Xujia Li#, Qi Jiang, Huijuan Qiu, Yuming Rong, Bokang Cui and Guifang Guo*(通讯作者), Analysis of Risk Factors for Distant Metastasis of Pancreatic Ductal Adenocarcinoma without Regional Lymph Node Metastasis and a Nomogram Prediction Model for Survival. Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2023, Article ID 2916974, 15 pages(IF=2.7)
8.Haohua Wang#, Roujun Peng#, Xiuxing Chen, Rui Jia, Chunyue Huang, Yuanyuan Huang, Liangping Xia and Guifang Guo* (通讯作者).Effect of HK2, PKM2 and LDHA on Cetuximab efficacy  in metastatic colorectal cancer. Oncology Letters, 2018 Apr;15(4):5553-5560.(IF=2.3). 
9.Zheng Yan#, BeiZhang, Yuan-Yuan Huang, Hui-Juan Qiu, Ping Chen, Gui-Fang Guo* （通讯作者）. Involvement of autophagy inhibition in Brucea javanica oil emulsion induced colon cancer cell death. Oncology Letters 2015（9）: 1425-1431, 2015. (IF=2.3).
10.Xiuxing Chen#, Yanfeng Chen, Xiuyu Cai, Dongsheng Zhang, Lei Fan, Huijuan Qiu,  Bei Zhang, Guifang Guo*（通讯作者）. Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta‑analysis. J Can Res Ther 2017;13:869-77. (IF=1.4)
11.Guifang Guo*# (第一及通讯作者), Xiuxing Chen#, Xiuyu Cai, Yanfeng Chen, Haohua Wang, Lei Fan,Long Bai, Huijuan Qiu, Bei Zhang. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy. Transl Cancer Res 2019;8(4):1137-1147. (IF=1.1)
12.Jinsheng Huang# , Jun Kan# , Teng Fan , Qi Quan , Xujia Li , Qi Jiang ,2,3,4 Bei Zhang*, and Guifang Guo*(通讯作者).  Efficacy of the Nourishing Yin and Clearing Heat Therapy Based on Traditional Chinese Medicine in the Prevention and Treatment of Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinomas: A Systematic Review and Meta-Analysis of Thirty Randomized Controlled. TrialsEvidence-Based Complementary and Alternative Medicine Volume 2022 , Article ID 4436361, 13 pages (IF=2.6)
13.Mai J#,   Zhong ZY#,  Guo GF#,  Chen XX,  Xiang YQ,  Li X,  Zhang HL,  Chen YH,  Xu XL,  Wu RY,  Yu Y,  Li ZL,  Peng XD,  Huang Y,  Zhou LH,  Feng GK,  Guo X,  Deng R,  Zhu XF, Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promotetumorigenesis in nasopharyngeal carcinoma. Theranostics 2019 May 26;9(12):3541-3554.  (IF=8.1)
14.Zhou Y#, Zhang Y#, Guo G#（共同第一）,  Cai X, Yu H, Zhang B*, Hong S*, Zhang li*. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer. Clin Transl Med, 2020, 10(1):1-9. (IF=7.9)
15.Wen-Zhuo He#, Chang Jiang#, Li-Li Liu, Chen-Xi Yin, Yu-Ming Rong, Wan-Ming Hu, Lin Yang, Lei Wang, Ya-Nan Jin, Xiao-Ping Lin, Shou-Sheng Liu, Jin-Sheng Huang, Sha-Sha He, Yu-Qing Liang, Hui-Juan Qiu, Bei Zhang, Wei Fan, Gui-Fang Guo*(共同通讯), Qiu-Xia Yang*, Liang-Ping Xia*. Association of Body Composition With Survival and Inflammatory Responses in Patients With Non-Metastatic Nasopharyngeal Cancer. Oral Oncol, 2020, 108:104771.  (IF=4.0)
16.Fang Wang#, Gui-fang Guo#（共同第一）, Hui-juan Qiu, Wen-zhuo He, Fei-fei Zhou, Xu-xian Chen, Pi-li Hu, Bei Zhang, Chen-xi Yin, Li Zhang, Liang-ping Xia*. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biol Med. 2012 Mar;9(1):38-43. (IF4.5)
17.Lin Yang; Zhenchong Xiong; Qiankun Xie; Wenzhuo He; Shousheng Liu; Pengfei Kong; Chang Jiang; Guifang Guo(共同通讯); Liangping Xia*. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer. BMC Cancer. 2018 May 11;18(1):558. (IF 3.0)
18.Lin Yang; Zhenchong Xiong; Wenzhuo He; Kunqian Xie; Shousheng Liu; Pengfei Kong; Chang Jiang; Guifang Guo(共同通讯); Liangping Xia*. Proximal shift of colorectal cancer with increasing age in different ethnicities, Cancer Manag Res. 2018 Aug 15;10:2663-2673. (IF 2.2)
19.W.-z. He; G.-f. Guo（共同第一）; C.-x. Yin; C. Jiang; F. Wang; H.-j. Qiu; X.-x. Chen; R.-m. Rong; B. Zhang; L.-p. Xia*. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer, Colorectal Dis. 2013.4.26; 15(8): e443-452. (IF3.0)
20.Ping Chen, Bei Zhang*, Guifang Guo* (共同通讯)，Liangping Xia, Huiuan Qiu. Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. The Chinese-German Journal of Clinical Oncology. 2014,13(5),229-234.
21.Guo GF#. Prognostic and predictive inflammation-based markers for advanced colorectal cancer of the elderly patients. Journal of Clinical Oncology. 2016;34(15):2.e15069 (IF=26.3)
22.Gui-fang Guo#, Bei Zhang, Yu-chen Cai, Rui-hua Xu, Xu-xian Chen, Pei-li Hu,  Hui-juan Qiu, Fang Wang, Liang-ping Xia  Wen-qi Jiang. Autophagy-related Proteins Beclin-1 and LC3 Predicting Cetuximab Efficacy in Advanced Colorectal Cancer. World Journal of Gastroenterology. 2011 November 21;17(43):4741-4838.（IF=2.5）
23.Gui-fang Guo#, Yu-chen Cai, Bei Zhang, Rui-hua Xu, Hui-juan Qiu, Liang-ping Xia, Wen-qi Jiang, Pei-li Hu, Xu-xian Chen, Feifei Zhou, Fang Wang. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Medical Oncology. 2011 Dec;28 Suppl 1:S197-203. Epub 2010 Nov 17. (IF=3.3). 

更新时间：2023年3月8日